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OBJECTIVES INTRODUCTION 
 To introduce the basic concepts of DIVA vaccines. 
 To explain the different types of vaccines that could be used in a DIVA 
strategy. 
 To describe DIVA strategies for several diseases that are important in 
animal health. 
 To describe different DIVA vaccines against Classical Swine Fever.  
 To design a DIVA strategy against Classical Swine Fever Virus. 
The term DIVA  is an acronym  for “Differentiating Infected from VAcci-
nated individuals” introduced by J.T van Oirschot. The DIVA strategy is 
formed by a vaccine and its companion diagnostic test (van Oirschot, 
1999).  
Countries that want to acquire the disease free-status following the vac-
cination path should introduce a DIVA strategy. 
Also the introduction of a DIVA strategy is an alternative to the stamping 
out strategy that disease free countries follow to control the outbreaks 
(Singh, 2015). 
DIVA STRATEGY AGAINST CSFV 
Fig 1.  Schematic description of the process to obtain an E2 subunit vaccine 
and its companion diagnostic test 
 Currently, the use of conventional vaccines remains essential for disease 
control and eradication, especially in endemic countries. 
 Although some of the DIVA strategies look promising, it is necessary to 
continue working in this area to improve the different types of vaccine as 
their corresponding diagnostic tests. 
 Chimeric vaccines are the most promising DIVA strategy against CSFV but  
further research must be implemented.  
 E2 subunit vaccines are economically and technically easy to produce. If 
their effectiveness and their diagnostic tests are improved, this type of DI-
VA vaccines will be a very promising strategy. 
 Dong X-N, Chen Y-H. Marker vaccine strategies and candidate CSFV marker vaccines. Vaccine. 2007;25(2):205-230. 
 Huang YL, Deng MC, Wang FI, Huang CC, Chang CY. The challenges of classical swine fever control: Modified live and E2 
subunit vaccines. Virus Res. 2014;179(1):1-11. 
 Meeusen ENT, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of veterinary vaccines. Clin Microbiol Rev. 
2007;20(3):489-510. 
 Pasick J. Application of DIVA vaccines and their companion diagnostic tests to foreign animal disease eradication. Anim 
Heal Res Rev. 2004;5(2):257-262. 
 Singh A. Modern Vaccines with Diva Capability : An Overview. RRJol. 2015;5(1):1-12.  
 Uttenthal A, Parida S, Rasmussen TB, Paton DJ, Haas B, Dundon WG. Strategies for differentiating infection in vaccinated 
animals (DIVA) for foot-and-mouth disease, classical swine fever and avian influenza. Expert Rev Vaccines. 2010;9(1):73-87. 
 van Oirschot JT. Diva vaccines that reduce virus transmission. J Biotechnol. 1999;73(2-3):195-205. 
REFERENCES 
CONCLUSIONS 
 
 
DIVA VACCINES APPLICATIONS 
 
 
DIVA VACCINES AGAINST CLASSICAL 
SWINE FEVER VIRUS (CSFV) 
Table 2. Types of marker vaccines developed against CSF  
Table 1. Description of different DIVA strategies against several diseases that are relevant in animal 
health 
